Community Magazine

ASH 2017: Dr. Thomas Kipps on the ROR1 Antibody, Cirmtuzumab

By Bkoffman
At ASH 2017 held in December in Atlanta, Dr. Thomas Kipps from the Moore Cancer Center at UCSD in San Diego, CA talked about an exciting new target for very specifically killing off chronic lymphocytic leukemia cells while sparing normal cells, including normal B lymphocytes.Dr. Kipps is one of the leading CLL researcher and has pioneered the work on a new antibody, cirmtuzumab that targets ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1).Because ROR1 is found nearly exclusively on cancer cells, an antibody against it may be the holy grail of antibodies, one that hits only the cancer cells with few off target effects.Take Aways:
  • ROR1 is an embryonic protein that may help the embryo develop new distant organs.
  • By birth it has largely disappeared from normal cells, but it can be found on the surface of many cancer cells including CLL cells.
  • ROR1 is involved in keeping CLL cells alive even when their B-cell receptor (BCR) is blocked by drugs such as ibrutinib.
  • Cirmtuzumab is an antibody against ROR1 that it very specific in hitting just that target.
  • Early studies used extremely low doses and it was only given four times.
  • Cirmtuzumab has proven to be safe in this phase 1 trial with no serious side effects including no significant infusion reactions.
  • The ROR1 antibody has a long half-life of 21 days.
  • While the early trial was for safety, there was clear evidence of efficacy in the few relapsed and refractory patients who received the higher doses of 1 mg per kilogram with a median progression free survival (PFS) of 259 days using that suboptimal dose.
  • The combination with ibrutinib appears to be result in higher kills rates of the chronic lymphocytic leukemia cells by blocking two separate signaling pathways necessary to keep the cells alive.
  • There are ongoing clinical trials looking at the combination of cirmtuzumab and ibrutinib. Here is a link:A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
  • While adding antibodies has historically not improved ibrutinib efficacy, cirmtuzumab is different in that it not just targeting a surface protein but is blocking a pro-survival pathway critical for CLL.
  • Cirmtuzumab also may be important in killing of cancer stem cells, which if proven, should reduce the risk of late relapses.
We have many exciting treatments for chronic lymphocytic leukemia, but cure is still elusive. It is still very early in the story, but he can sense Dr. Kipps’ excitement and his hope that cirmtuzumab, when used in smart combinations might be part of the mix that leads to what we all dream of, namely being able to say: I used to have CLL.Here is my interview with my doctor, Dr. Thomas Kipps from UCSD. It’s 17 minutes, but Dr. Kipps is a great teacher.Here is a link to the referenced ASH abstract: Durable and Specific Inhibition of ROR1 Signaling Associates with Prolonged Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Treated with CirmtuzumabFor more of ROR1 and cancer stem cells, see this prior interview from ASH 2014 with Dr. Kipps.Thanks for reading.Stay strong.We are all in this togetherBrianIf you want a personal response, or just want to stay in touch, please email me at [email protected] I have no other way of contacting. Thanks. Stay strong. After all, we are all in this together. And please visit our website: http://cllsociety.org for the latest news and information.

You Might Also Like :

Back to Featured Articles on Logo Paperblog

These articles might interest you :

  • ✔635.Arbories Memorial Sports Ground

    ✔635.Arbories Memorial Sports Ground

    Padiham 4-0 Litherland REMYCANorth West Counties FL - Premier DivisionSaturday 22nd September 2018 Padiham was originally a rural village lying by the River... Read more

    The 23 September 2018 by   Smidrophenia
    SOCCER, SPORTS
  • Eco Park

    Park

    Saturday wasn't a busy day. We didn't have any birthday parties, Brandon didn't have work to do, and our household chores weren't very many. Read more

    The 23 September 2018 by   Sherwoods
    FAMILY, PARENTING
  • Coheed and Cambria with Protest the Hero and Crown Lands

    Coheed Cambria with Protest Hero Crown Lands

    Coheed and Cambria rolled into Toronto with their progressive metal sound on Thursday night for the Unheavenly Tour with Protest the Hero and Crown Lands. It wa... Read more

    The 23 September 2018 by   Phjoshua
    LIFESTYLE, SELF EXPRESSION
  • Lockheed Martin C-130 Hercules

    Lockheed Martin C-130 Hercules

    @ Nellis AFB, NV November 2007 Two service members are silhouetted against the late afternoon sky after watching the Aviation Nation airshow from their unique... Read more

    The 23 September 2018 by   Htam
    PHOTOGRAPHY, SOCIETY
  • 10 Attributes Of The Ideal New Venture Job Candidate

    Attributes Ideal Venture Candidate

    In a corporate environment, the focus of a job interview has long been demonstrating your match to the skills and experience outlined in the job description. Read more

    The 23 September 2018 by   Martin Zwilling
    BUSINESS, CAREER
  • BREAKING: It’s ‘Inconclusive’! INEC Says No Winner In Osun Governorship Election

    The Independent National Electoral Commission (INEC) has declared Saturday’s Osun State governorship election “inconclusive”. Announcing the results on Sunday... Read more

    The 23 September 2018 by   Naijapary
    SOCIETY, A-CLASSER
  • Whelmed Over

    Whelmed Over

    I have to admit I feel overwhelmed by the task. You see, I spent twelve years living in a town that went from one small used bookstore to none. Read more

    The 23 September 2018 by   Steveawiggins
    POLITICS, RELIGION, SOCIETY

Magazines